Sarcoidosis of the CNS: Comparison of Unenhanced and Enhanced MR Images

Sarcoidosis involving the CNS has a predilection for the leptomeninges, although parenchymal involvement occurs. We retrospectively evaluated the appearance of CNS sarcoidosis on unenhanced and enhanced MR images. MR studies were abnormal in 17 of 20 patients with CNS sarcoidosis. In all 17 patients, meningeal disease was detected on the gadopentetate-dimeglumine-enhanced T1-weighted images; the disease was detected on unenhanced images in three patients. Well-defined leptomeningeal patterns of enhancement were present in 15 patients. Other areas of involvement were the dura; brain parenchyma including hypothalamus, periventricular white matter, and ventricular ependyma; optic chiasm; and pituitary gland.

Gadopentetate dimeglumine optimally evaluates meningeal disease and highlights the importance of the leptomeninges and Virchow-Robin spaces in the pathogenesis of CNS sarcoidosis. Enhanced MR is the preferred imaging technique for the evaluation of CNS sarcoidosis.


Neurologic manifestations of sarcoidosis occur in 5% of patients with this disease [1]. Postmortem studies demonstrate CNS and meningeal disease in as many as 14% of patients with known systemic sarcoidosis [2, 3]. Intracranial involvement is most often a diffuse or focal granulomatous leptomeningitis. Parenchymal inflammation is seen also. The MR appearance of neurosarcoidosis has been described [4–8]. Unenhanced MR is superior to CT in the evaluation of hypothalamic and periventricular involvement [3, 4]. However, unenhanced MR does not optimally evaluate inflammation of the meninges and does not evaluate the integrity of the blood-brain barrier. The use of gadopentetate dimeglumine has been recommended for brain MR imaging to evaluate the blood-brain barrier and whenever extraxial disease is suspected [9–13]. In this study, we describe the gadopentetate-dimeglumine-enhanced MR appearance of CNS sarcoidosis and compare it with the unenhanced MR appearance.

Materials and Methods

Twenty patients with neurosarcoidosis underwent MR examinations of the brain before and after administration of gadopentetate dimeglumine. All but three patients had biopsy-proven systemic sarcoidosis. In those three patients, intracranial biopsies showed granulomatous inflammation consistent with sarcoidosis. The diagnosis of neurosarcoidosis was made clinically in the other 17 patients. There were 11 women and nine men 21–58 years old (average, 38 years). Table 1 is a clinical summary of the patients involved in this study.

MR examinations were performed on 1.5-T (n = 16 patients), 1.0-T (n = 1 patient), or 0.5-T (n = 3 patients) MR imagers. All unenhanced examinations used at least three techniques: T1-weighted spin echo (SE), 500–600/20–25/2 (TR/TE/excitations); intermediate SE, 2000–3200/30–40/1–2; and T2-weighted SE, 2200–3200/80–100/1–2. Section thickness was 5 or 7 mm, with an intersection gap of 1–2.5 mm. Gadopentetate dimeglumine (Magnevist, Berlex...
Laboratories, Wayne, NJ) was given in a concentration of 0.1–0.15 mmol/kg at a rate of 15–30 ml/min (Kashanian FK et al., presented at the annual meeting of the American Society of Neuroradiology March 1989). Patients were studied with short T1-weighted scans after the administration of contrast material. The matrix was 256 x 256 for all T1-weighted images and for most intermediate and T2-weighted images. A 128 x 256 matrix was used in a few instances.

In a nonblinded review, we retrospectively analyzed each set of images for abnormalities affecting the following areas: meninges, falx, hypothalamus/pituitary, periventricular white matter, parenchyma, and ependyma.

Results

The results of brain MR in our patients are summarized in Table 2. The enhanced MR studies revealed additional areas of involvement not suspected on the unenhanced examinations in 17 patients. We identified multiple lesions in most patients; for example, multiple meningeal foci, hypothalamic infiltration, and white or gray matter lesions. The scope and multiplicity of the variable MR findings on patients is reflected in Table 3. Of particular note is the observation of multiple areas of involvement that were visualized only on enhanced MR. Leptomeningeal involvement (Figs. 1–5) was most striking since none of the leptomeningeal disease was detected on unenhanced MR. Of interest is the observation of internal auditory canal enhancement in three patients with diffuse leptomeningeal disease. Other areas where enhanced MR was superior included the dura (Figs. 1 and 5), hypothalamus, and pituitary/infundibular disease (Figs. 1, 3, and 6). Periventricular enhancement (Figs. 6 and 7) was very prominent in several patients and could not be predicted on the basis of the appearance on the T2-weighted images.

Clinical Correlation and Follow-up Evaluation

The clinical summary of our patients is presented in Table 1. Three patients had a clinical diagnosis of CNS sarcoidosis with cranial neuropathies but had normal MR studies. Two of these patients were being treated with 40 mg/day of prednisone at the time of scanning.

Follow-up gadopentetate-dimeglumine–enhanced MR studies were available in four patients. Three of the patients were treated with 20–65 mg/day of prednisone. In one patient (case 13), a right cerebellopontine angle granuloma markedly decreased in size after 2 months of therapy but then stabilized over the next 12 months. A second patient (case 7, Fig. 6) had resolution of abnormal enhancement around the third ventricle but persistent chiasmatic enhancement after 6 months of corticosteroid therapy (40 mg of prednisone/day tapered to 10 mg/day). In a third patient (case 4), an unenhanced study initially revealed brain edema adjacent to an area of slight falcine thickening. Follow-up unenhanced and
TABLE 2: Summary of Brain MR Imaging in Patients with CNS Sarcoidosis

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Meningeal Disease</th>
<th>Leptomeningeal</th>
<th>Dural</th>
<th>Hypothalamus and Pituitary</th>
<th>Periventricular Lesions</th>
<th>Ependymal Enhancement</th>
<th>Parenchymal Involvement</th>
<th>Hydrocephalus</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>G</td>
<td>U</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>Edema, encephalopathy, meningo-vascular pathology (G/U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>G/U</td>
<td>None</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>Edema (U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>G/U</td>
<td>G/U</td>
<td>No</td>
<td>Two parenchymal nodules without surrounding edema (G/U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Diffuse (G)</td>
<td>G</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Focal (G)</td>
<td>None</td>
<td>G</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Focal (G)</td>
<td>None</td>
<td>None</td>
<td>U</td>
<td>Yes</td>
<td>Cerebellar peduncle infarct (U)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Focal (G)</td>
<td>None</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Focal (G)</td>
<td>None</td>
<td>G</td>
<td>G/U</td>
<td>No</td>
<td>Enhancing cerebellar peduncle and posterior temporal lesions (G/U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Focal (G)</td>
<td>None</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>None</td>
<td>G</td>
<td>G</td>
<td>None</td>
<td>No</td>
<td>Internal capsule lacune (U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>None</td>
<td>G/U</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>Shunted</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
<td>None</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>No</td>
<td>None</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>None</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>G</td>
<td>G/U</td>
<td>No</td>
<td>Edema, confluent nodules causing mass in temporal lobe (G/U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Diffuse (G)</td>
<td>G/U</td>
<td>None</td>
<td>G/U</td>
<td>No</td>
<td>Edema, encephalopathy (G/U)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Diffuse (G)</td>
<td>None</td>
<td>G</td>
<td>None</td>
<td>Yes</td>
<td>None</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Diffuse (G)</td>
<td>G</td>
<td>None</td>
<td>None</td>
<td>No</td>
<td>Edema, subfascial mass extending into frontal lobe (G/U)</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Note.—G = enhancing abnormality identified on gadopentetate-dimeglumine–enhanced MR; U = abnormality identified on unenhanced MR.

TABLE 3: Summary of MR Characteristics of CNS Sarcoidosis

<table>
<thead>
<tr>
<th>Involved Area</th>
<th>T2-Weighted Images</th>
<th>T1-Weighted Images</th>
<th>T1-Weighted Images with Gadopentetate Dimeglumine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptomeninges</td>
<td>No lesions detected</td>
<td>No lesions detected</td>
<td>Diffuse involvement (n = 10); focal involvement (n = 5)</td>
</tr>
<tr>
<td>Dura</td>
<td>Hypointense plaque (n = 3); isointense mass (n = 1) [4]</td>
<td>Isointense mass (n = 1)</td>
<td>Focal mass/plaque (n = 3); sheetlike involvement (n = 3) [13]</td>
</tr>
<tr>
<td>Pituitary and infundibulum</td>
<td>No lesions detected</td>
<td>Isointense enlargement (n = 5)</td>
<td>Increased enhancement of infundibulum (n = 5) and pituitary (n = 1)</td>
</tr>
<tr>
<td>Optic chiasm</td>
<td>No lesions detected</td>
<td>Enlarged chiasm (n = 5) [4]</td>
<td>Enhancement of chiasm (n = 6) and optic nerves/tracts (n = 2)</td>
</tr>
<tr>
<td>Hypothalamus</td>
<td>Hyperintensity in anterior perforated substance (n = 4) and anterior commissure (n = 2) [14]</td>
<td>No lesions detected</td>
<td>Enhancement of hypothalamic area (n = 4) and fornix (n = 2)</td>
</tr>
<tr>
<td>White matter</td>
<td>Vasogenic edema (n = 6); patchy periventricular/subcortical lesions (n = 6) [4, 6, 8]</td>
<td>No lesions detected</td>
<td>Enhancement near lateral ventricles (n = 3), near third ventricle (n = 3), and near fourth ventricle (n = 3)</td>
</tr>
<tr>
<td>Gray matter</td>
<td>Heterogeneous infiltrations with edema (n = 5) and without edema (n = 1) [4, 6, 7]</td>
<td>Hypointense area (n = 2)</td>
<td>Small discrete nodules (n = 5); linear/confluent nodular areas in continuity with pial disease (n = 4)</td>
</tr>
<tr>
<td>Ventricles</td>
<td>Hydrocephalus with periventricular edema (n = 3); &quot;ballooning&quot; of fourth ventricle (n = 1)</td>
<td>Hydrocephalus (n = 3) [4, 6]</td>
<td>Periaqueductal enhancement (n = 2); fourth ventricle enhancement (n = 4)</td>
</tr>
</tbody>
</table>

Note.—There was more than one area of involvement in most patients. Cited literature illustrates characteristics of CNS sarcoid.
enhanced studies 10 months later revealed marked multifocal meningeal and hypothalamic enhancement (Fig. 1), but the brain edema had resolved without corticosteroid administration. The fourth patient (case 5), with extensive meningeal and hypothalamic involvement, was evaluated after 6 months and again after 10 months of suboptimal therapy (80 mg/day of prednisone was prescribed but the patient repeatedly missed doses). Brain edema initially improved but then remained unchanged. Extensive meningeal and parenchymal enhancement was present on the latest contrast-enhanced...
Fig. 3.—Case 5: 21-year-old man with leptomeningeal and hypothalamic involvement.

A, Coronal enhanced T1-weighted image. Note basilar leptomeningeal enhancement. Disease extends through anterior perforated substance into hypothalamus (arrowheads).

B, T2-weighted axial image reveals edema in base of brain (arrows).

Fig. 4.—Case 2: 49-year-old man with meningoencephalovasculopathy.

A, Contrast-enhanced T1-weighted parasagittal image. Note extension of granulomatous disease deep into brain along Virchow-Robin spaces (straight arrows). Small area of enhancement (curved arrow) and large areas of hypointensity are noted in cerebellum.

B, T2-weighted coronal image. Cerebral cortical disease (straight arrows) and vasogenic edema (curved arrow). Cerebellar hyperintensity is not associated with mass effect and probably reflects chronic ischemic disease (arrowheads).

MR study (Fig. 3). Visual symptoms had increased. In case 17, CNS involvement increased despite chemotherapy with a regimen of prednisone (15 mg/day) and cyclosporine (trough blood level of 228 ng/ml).

Discussion

Our data concur with pathologic studies of CNS sarcoidosis that have shown that the most common sites of disease activity are the basal meninges; basal midline structures, especially hypothalamus; infundibulum; pituitary gland; and floor of the third ventricle [1, 14]. The pathologic manifestations of CNS sarcoidosis consist of granulomatous dural invasion with plaquelike or focal masses [4, 15], leptomeningitis, parenchymatous infiltration especially along the perivascular spaces of Virchow-Robin [16], and coalescence of granulomata in the brain parenchyma producing an intraaxial tumor [17]. Periventricular lesions in CNS sarcoidosis have been described also [1, 5, 8, 18].

Prior to the release of gadopentetate dimeglumine, our recommendation had been to perform both MR and contrast-enhanced CT [4]. Contrast-enhanced CT was most valuable in the detection of basal meningeal disease, while conventional unenhanced MR revealed involvement of the hypothalamus, optic chiasm, and brain parenchyma including periventricular white matter disease. However, this combined technique is still inadequate for evaluation of the meninges. Contrast-enhanced CT is suboptimal because of the Hounsfield artifact problem [13]. Unenhanced MR is suboptimal because of the poor contrast between bone, CSF, and meninges on both T1- and T2-weighted sequences.

The introduction of gadopentetate dimeglumine markedly increased the sensitivity of MR to the presence of meningeal disease [12]. We detected meningeal disease on the enhanced MR images in 17 patients, compared with unenhanced MR detection in three patients.

Sarcoidosis primarily involves the leptomeninges, which include both arachnoid and pia mater. The leptomeningeal pattern is recognized on enhanced MR images because the enhancement follows the contour of the brain, extending into the cortical sulci. Pial involvement can be differentiated from arachnoid involvement along the brainstem, where the arachnoid is separated from the pia by CSF in the cisternal subarachnoid space (Fig. 1). Here the pia mater is attached
Fig. 5.—Case 6: 27-year-old man with dural, leptomeningeal, and parenchymal disease.
A, Unenhanced T1-weighted coronal image reveals subtle abnormalities that are detectable when compared with enhanced image (B).
B, Contrast-enhanced T1-weighted coronal image. Nodular enhancing sarcoid granulomatous mass is on right (arrowheads). There is erosion of inner table of calvaria (straight arrow). Falx is involved also (curved arrow).
C, Contrast-enhanced T1-weighted axial image. Subtle leptomeningeal enhancement is noted in many sulci. Cortical nodule in left temporal lobe was seen only on enhanced image (arrows).
D, T2-weighted axial image at same level is normal.
E, T2-weighted axial image near convexity. Brain edema is present (arrows).

Fig. 6.—Case 7: 58-year-old woman with periventricular and hypothalamic disease.
A, Contrast-enhanced T1-weighted coronal image. Enhancing tissue along margin of third ventricle (arrows) causes slight compression of ventricle.
B, Contrast-enhanced T1-weighted image after 6 months of prednisone therapy. There has been resolution of enhancement and relief of mass effect (arrows). Note rounded appearance of third ventricle compared with A.
C, T2-weighted axial image (pretreatment). Note periventricular areas of increased intensity (arrows).
Fig. 7.—Case 11: 57-year-old man with parenchymal disease.
A, Contrast-enhanced T1-weighted axial image. Enhancing lesion involves subcortical and periventricular areas (arrows).
B, T2-weighted axial image. Small areas of increased intensity are present but there is no evidence of vasogenic edema (arrows).
C, Contrast-enhanced T1-weighted axial image in posterior fossa shows enhancing lesion in right middle cerebellar peduncle (arrow).
D, T2-weighted axial image. Small area of increased intensity indicates presence of granulomatous lesion (arrow). Note absence of vasogenic edema.

intimately to the neuroparenchyma and is detached from the arachnoid.

Capillary endothelial cells of the arachnoid have tight junctions, as do those in the brain, creating a CSF-blood barrier [19]. The basement membrane of the pia and adherent astrocytic foot processes creates a pial-brain barrier. In an animal model of meningeal carcinomatosis, Frank et al. [20] have shown that gadolinium not only enhances the infiltrated meninges but leaks into the contiguous CSF. Disruption of the capillary endothelial tight junctions of the arachnoid mater by disease most likely accounts for the passage of gadolinium into the adjacent pia mater and subarachnoid space [21].

Penetrating cerebral vessels are invested in a leptomeningeal sheath with a potential space continuous with subarachnoid space (the Virchow-Robin space) [16]. The first effect of leptomeningitis is meningeal vascular hyperemia. The ensuing inflammatory exudate spreads in the subarachnoid space and into the Virchow-Robin spaces to a variable degree. Infiltration may occur along the surface of the brain or extend deep into the brain along the Virchow-Robin spaces. The infiltrating process may appear intraparenchymal on gross examination or on MR images, but histologically the disease may remain restricted to the leptomeninges. A meningoencephalovascularopathy occurs when the pial-brain barriers are invaded by the inflammatory process [20].

Although we do not have direct pathologic correlation, progressive severity of the breakdown in the pial barriers can be inferred by noting the thickness of the pial enhancement, particularly along the brainstem. We speculate that if pial enhancement is seen as a sharply defined fine line there is disruption of the barriers, but probably no infiltration along perivascular spaces into the brain (Fig. 1). If the pial enhancement is thick and ragged (Fig. 4), then invasion along perivascular spaces has probably occurred, causing a meningoencephalovascularopathy, as has been shown on contrast-enhanced CT with pathologic correlation [16]. Enhancing
linear and nodular areas extending from the pial surface into the white matter indicate infiltration along Virchow-Robin spaces (Figs. 3 and 4).

Inflammation originating in the Virchow-Robin space can spread and coalesce, in the case of sarcoidosis, into granulomatous masses (Figs. 5 and 7). When this occurs there is often adjacent edema due to disruption of the blood-brain barrier and increased vascular permeability that extends along white matter fascicles (vasogenic edema) [22−24]. However, areas of blood-brain barrier disruption may be present without associated edema (Fig. 7). Vasogenic edema should be differentiated from chronic ischemic gliosis secondary to vasculopathy and perforating vessel occlusion caused by infiltration of Virchow-Robin spaces [16].

Dural involvement, although less frequent, is more likely than leptomeningeal infiltration in sarcoidosis, but dural leptomeningeal involvement is noted previously [4], the only manifestations of CNS sarcoidosis on unenhanced MR images may be subtle falci ne thickening or focal plaque formation. We have seen meningeval sarcoid produce a mass over the convexity [4], in the middle cranial fossa, and in the cerebellopontine angle. The varied appearances of CNS sarcoidosis on unenhanced MR are reviewed in Table 3. Typically there is intense enhancement in the abnormal area if gadopentetate dimeglumine is administered (Fig. 5). Falci ne disease may develop as a consequence of local leptomeningeal granulomatous inflammation.

Sze et al. [13] anecdotally reported one patient with CNS sarcoidosis in whom the most striking abnormality was diffuse dural enhancement with minimal leptomeningeal enhancement.

Any portion of the brain can be affected by sarcoidosis, but the basal portion is the most common location [2, 25]. This correlates with recent observations that CSF-filled Virchow-Robin spaces are routinely visualized in the basal areas of the brain [26, 27]. Anatomically this area includes the anterior perforated substance, which is characterized by numerous penetrating, small blood vessels [28]. In addition, the blood-brain barrier is absent in the tuber cinereum, hypophysis, and preoptic region [24].

Hypothalamic dysfunction is the most common manifestation of CNS parenchymatous disease in sarcoidosis [1]. Seven of our patients had disease of the hypothalamic-pituitary axis (Figs. 1, 3, and 6). Pituitary infiltration by sarcoidosis is often reported histologically in patients with systemic sarcoidosis, but we are unaware of any report in the imaging literature [2, 29]. Optic chiasm and infundibular "thickening" are other common manifestations of CNS sarcoidosis on MR. The optic chiasm is enveloped by pia mater and therefore is subject to granulomatous leptomeningitis. Thickening of the chiasmatic pia as well as infiltration of the optic pathway can cause enlargement of the chiasm.

Seven of our patients had diffuse or focal areas of increased intensity in the periventricular white matter on T2-weighted images (Figs. 6 and 7). In two patients, periventricular white matter disease was detected only on T2-weighted images. Periventricular white matter lesions in CNS sarcoidosis have been reported previously [4, 8, 30]. In two patients the periventricular white matter disease resembled the common pattern of multiple sclerosis [31, 32]; in three patients the pattern was more typical of ischemic disease [33, 34]. In two patients probable mild interstitial edema was associated with hydrocephalus. One patient had extensive bilateral cerebellar gliosis or white matter infarctions that were hyperintense on T2-weighted images. The typical pattern of vasogenic edema was not seen and there was only mild meningeal enhancement around the cerebellum after administration of gadopentetate dimeglumine.

Hydrocephalus is a common manifestation of CNS sarcoidosis [1−3]. Granulomatous leptomeningitis may cause extraventricular obstructive hydrocephalus (communicating hydrocephalus) [6] or fourth ventricular outlet obstruction [18, 35]. Granulomatous compression of the aqueduct [16] and fourth ventricle [18] also may occur. Infiltration of the ependyma and choroid plexus may alter CSF dynamics resulting in hydrocephalus [2, 18]. Ependymal enhancement and prominent enhancement of the choroid plexus at the foramina of Luschka was seen in one of our patients (case 8).

There are several possible explanations for normal gadopentetate-dimeglumine–enhanced MR studies in our three patients with cranial nerve involvement. There may be extra-axial involvement of the cranial nerves. There may be focal leptomeningeal or endoneurial disease that is too small to visualize or does not disrupt the blood-brain and pial barriers [2]. For example, some patients with aseptic and bacterial meningitis have normal gadopentetate-dimeglumine MR studies even if extraventricular obstructive hydrocephalus is present [11, 36]. Studies of carcinomatous meningitis have suggested that a minimum amount of tumor is required before enhancement is observed in the meninges on the enhanced images [13, 20]. There may have been reestablishment of the CSF-pial-brain barrier, thus preventing contrast enhancement despite the presence of active meningeal disease [20, 36]. We observed one patient in whom abnormal periventricular enhancement resolved after 6 months of therapy (Fig. 6).

The differential diagnosis of CNS sarcoidosis is quite broad. None of the unenhanced MR or gadopentetate-dimeglumine–enhanced manifestations of sarcoidosis are specific. Tuberculosis [37], fungal diseases, and bacterial [11, 36, 38] infections can produce diffuse leptomeningitis that may enhance on gadopentetate-dimeglumine MR. Meningeal carcinomatosis, leukemia, and lymphoma are indistinguishable from CNS sarcoidosis on MR [13]. We have seen diffuse meningeal enhancement following subarachnoid and subdural hemorrhage. Diffuse dural fibrosis following ventricular shunting has been shown to enhance intensely, but leptomeningeal involvement has been absent [39]. Less common diseases that could be diagnostic considerations in some cases include meningiomatosis [40], lipogranulomatosis [41], and cranial pachymeningitis [42].

Summary

1. It is important to understand that CNS sarcoidosis is foremost a leptomeningeal disease and the Virchow-Robin spaces are extensions of the leptomeninges. Study of gadopentetate-dimeglumine–enhanced images of the brain has solidified this concept.
ENHANCED MR IN CNS SARCOIDOSIS

2. We recommend the use of gadopentetate dimeglumine in all patients being evaluated for CNS sarcoidosis. Unenhanced MR alone is unlikely to reveal the important leptomeningeal manifestations of this disease.

3. Normal unenhanced and gadopentetate-dimeglumine-enhanced MR does not exclude CNS sarcoidosis, especially in patients with only cranial neuropathy or in those patients being treated with corticosteroids.

4. Enhancement with gadopentetate dimeglumine can resolve with corticosteroid treatment.

ACKNOWLEDGMENTS

We thank Stephen Reich, John Griffin, Claudio Levin, Penelope Scott, Gary Cassel, Justin McArthur, Thomas Price, Thomas Kowalski, Barbara Joslow, Philip Pulaski, Ben Frisberg, Andy Barbash, Robert Baumgartner, Sharon Seltzer, Patricia Behlmer, and Don Wood for patient referrals and Andrea Zarin and Shirley Zubrek for organizational and administrative assistance.

REFERENCES

34. Tien RD, Johnson PD, Spetzler RF, et al. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke 1986;17:1090–1097
37. Suss RA, Resta S, Diehl JT. Persistent cortical enhancement in tuberculous meningitis. AJNR 1987;8:716–720